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Abstract
Common genetic variants have been shown to explain a fraction of the inherited variation for many common diseases and
quantitative traits, including height, a classic polygenic trait. The extent to which common variation determines the
phenotype of highly heritable traits such as height is uncertain, as is the extent to which common variation is relevant to
individuals with more extreme phenotypes. To address these questions, we studied 1,214 individuals from the top and
bottom extremes of the height distribution (tallest and shortest ,1.5%), drawn from ,78,000 individuals from the HUNT
and FINRISK cohorts. We found that common variants still influence height at the extremes of the distribution: common
variants (49/141) were nominally associated with height in the expected direction more often than is expected by chance
(p,5610
228), and the odds ratios in the extreme samples were consistent with the effects estimated previously in
population-based data. To examine more closely whether the common variants have the expected effects, we calculated a
weighted allele score (WAS), which is a weighted prediction of height for each individual based on the previously estimated
effect sizes of the common variants in the overall population. The average WAS is consistent with expectation in the tall
individuals, but was not as extreme as expected in the shortest individuals (p,0.006), indicating that some of the short
stature is explained by factors other than common genetic variation. The discrepancy was more pronounced (p,10
26)i n
the most extreme individuals (height,0.25 percentile). The results at the extreme short tails are consistent with a large
number of models incorporating either rare genetic non-additive or rare non-genetic factors that decrease height. We
conclude that common genetic variants are associated with height at the extremes as well as across the population, but
that additional factors become more prominent at the shorter extreme.
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Introduction
Height is a highly heritable trait, with estimates of heritability as
high as 90% [1]. Recent genome-wide association studies of height
have discovered over 180 common variants associated with height
[2]. These variants have small effect sizes and collectively explain
approximately 10% of the heritability. While these 180 common
variants are robustly associated with height when studied as a
quantitative trait in the general population, it is not known
whether these variants have similar associations with stature in
individuals at the extreme tails of the height distribution. If these
common variants do not show the expected association with
stature at the extremes (based on their continuous distribution
effect sizes), then other factors beyond common variants must
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scenarios, one possible explanation is the existence of rare or low
frequency variants with larger effect sizes, which have been
proposed to explain a portion of the heritability not accounted for
by the known common variants [3–5] and which may provide
novel biological insights into mechanisms that affects height.
Understanding the role of common variants in the tails of the
height distribution will also provide methodological insight into the
utility of extreme tails analysis for future genetic studies of
quantitative traits.
In this paper, we describe our approach to determine whether
common alleles known to be associated with height in the general
population have the expected distribution in individuals from the
extremes of the height distribution. We used DNA samples from
individuals with extreme heights from two population-based
cohorts of Finnish (FINRISK) and Norwegian (HUNT) ancestry
and genotyped them for common variants known to be associated
with height. Under a polygenic model in which there are many
variants and each variant additively contributes a small effect to
the phenotype, we found that for individuals within ,2.81
standard deviations of the mean, the common variants have the
predicted associations with height, consistent with their effect sizes
estimated from the previous population study [2]. However, in
individuals with more extreme short stature (the shortest 0.25% of
the distribution), common variants play a less prominent role in
explaining phenotype, and the data are consistent with various
models in which rare variants, non-additive effects or rare non-
genetic factors contribute to short stature in these individuals.
Results
Individual common variants are associated with height in
the extremes
We attempted to genotype SNPs at the 180 loci previously
associated with height in individuals from the short and tall
extremes of the FINRISK and HUNT cohorts and then
performed association analyses for each SNP with height using
the Cochran-Mantel-Haenszel test and logistic regression respec-
tively. In FINRISK, SNPs at 158 of the height loci were
successfully genotyped in 181 short and 192 tall individuals from
the 1% tails of the height distribution. In the HUNT study, SNPs
at 160 of the height loci were successfully genotyped in 385 short
and 456 tall individuals from the ,1.5% tails of height. Here we
focus on the 279 short and 309 tall individuals from the 1% tails of
the HUNT study, so as to provide consistency with the FINRISK
study. In both cohorts, the majority of SNPs had effect directions
consistent with the published results [2] (HUNT 137/160,
p,0.0001; FINRISK 122/155, p,0.0001) and there was a
significant enrichment in SNPs reaching nominal significance for
association with height (Table S1; Table S2). We then combined
the data from both cohorts in a meta-analysis of 141 overlapping
loci (Table S3). Ninety-one percent of SNPs (128/141, p,0.0001)
had directions of effect consistent with previously published results
[2] and 49 SNPs had p-values,0.05, as opposed to 7 expected by
chance (p,5610
228). This result confirms that, as a group, SNPs
found to be associated with height in the general population are
also associated with height at the extremes of the phenotypic
spectrum.
The effect sizes of individual common variants on height
are similar in the extremes and the general population
We next tested whether the observed odds ratios (OR) are
consistent with the expected odds ratios, based on the previously
estimated effect sizes from the GIANT study [2] and study specific
allele frequencies (see Materials and Methods). Overall, the
number of SNPs with observed odds ratio greater than expected
odds ratios was no different than expectation under the model of
equal effect sizes in extremes and the general population (HUNT
79/160 SNPs, p=0.94; FINRISK 75/155 SNPs, p=0.48 and
combined 75/141, p=0.45); (Table S1; Table S2 and Table S3).
Next, for each SNP we tested for a difference between the
expected and observed odds ratio in the individual studies and in
the meta-analysis. Overall there were no more or fewer significant
associations than would be expected under the equal effect size
model (Figure S1). This result demonstrates that the individual
SNPs have similar effects at the extremes as in the general
population.
Weighted Allele Score (WAS) analysis: The additive effect
of the common variants differs significantly from
expected in the short extremes
After determining that the individual SNPs have similar effects
at the extremes of the height distribution as in the general
population, we then performed additional analyses on the
combined set of height-associated variants. We asked whether
extremely short and extremely tall individuals show overall
enrichment of height-decreasing and height-increasing alleles,
respectively, to the extent expected under a purely polygenic
additive model. If the enrichment is less than expected, this result
would suggest that the common variants are not explaining as
much of the phenotypic variation in the extremes as in the general
population. To test this possibility, we first calculated the weighted
allele score (WAS) for each individual using the height-associated
SNPs previously described. The WAS is the cumulative effect of all
of the SNPs on height weighted by each SNP’s estimated effect size
(b). In Figure 1, we show a plot of each individual’s WAS based on
the 143 loci genotyped in both cohorts versus the individual height
Z-scores. As expected, the WAS are significantly different between
the tall extremes and the short extremes (p,3610
286), with
individuals in the tall extreme having higher WAS on average than
individuals in the short extremes.
We then tested whether the WAS in the short and tall groups are
within expectations based on the population specific allele
Author Summary
Although there are many loci in the human genome that
have been discovered to be significantly associated with
height, it is unclear if these loci have similar effects in
extremely tall and short individuals. Here, we examine
hundreds of extremely tall and short individuals in two
population-based cohorts to see if these known height
determining loci are as predictive as expected in these
individuals. We found that these loci are generally as
predictive of height as expected in these individuals but
that they begin to be less predictive in the most extremely
short individuals. We showed that this result is consistent
with models that not only include the common variants
but also multiple low frequency genetic variants that
substantially decrease height. However, this result is also
consistent with non-additive genetic effects or rare non-
genetic factors that substantially decrease height. This
finding suggests the possibility of a major role of low
frequency variants, particularly in individuals with extreme
phenotypes, and has implications on whole-genome or
whole-exome sequencing efforts to discover rare genetic
variation associated with complex traits.
Common Variants9 Effects on Height Extremes
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assuming a purely polygenic model. To generate the distribution
of WAS under these expectations, we simulated populations that
mimicked our ascertainment of extreme samples from the HUNT
and FINRISK populations (see Materials and Methods). For each
cohort, we compared the observed mean WAS with the
distribution of mean WAS under the simulated model (Figure S2
and Figure S3). For the HUNT study the sample of 1224
individuals from the middle of the distribution suggest our
modeling is behaving as expected (Figure S2). Finally, we analyzed
the data by combining both studies using the 143 SNPs present in
both data-sets (Figure 2). In each study separately and in the
combined analysis, the mean observed WAS for the tall individuals
was within expectation, but we observed a significant upward
deviation of the mean observed WAS in the short extremes
(p=0.006 for the combined-analysis). These results suggest that
the collective effect of the common variants in the short extremes
do not account for as much of the phenotypic variation in height
as predicted from the effects seen in the general population.
The reduced effect of common variants is limited to the
most extreme short individuals
Having established that the common variants do not explain as
much phenotypic variation in the short extremes, we then sought
to determine if this finding was accentuated in individuals with the
most extreme short stature. We stratified our analysis in several
ways (Figure 2; Figure S2; Figure S3). First, we removed the most
extreme individuals: those below the 0.25 percentile and above the
99.75 percentile. In the combined cohorts, the mean observed
WAS in the short extremes was no longer significantly different
than expected (p=0.526), indicating that the shift in WAS is driven
by the most extremely short individuals. To further explore this
hypothesis, we then selected more extreme individuals at two
thresholds, including only the top and bottom 0.5% or 0.25% of
the population (See Materials and Methods). For both strata, there
was a more pronounced deviation of the mean observed WAS in
the short extremes (p=7.12610
26 and p=9.88610
27 for the
0.5% and 0.25% extremes respectively), but again no deviation in
the tall extremes. Similar observations occurred when we analyzed
the cohorts separately using the same stratification procedure
(Figure S2; Figure S3). We repeated the analysis using Z-scores
based on inverse normal transformation, and with the three 26
SD outliers removed, and the results were essentially unchanged.
The difference observed in the WAS analysis is also supported by
the individual SNP analysis: when we performed the combined
analysis described above for the 0.25% extremes rather than the
entire cohort, 60% (84/139) of the SNPS have an observed effect
size smaller than expected (p=0.02) (Table S4). This analyses
clearly suggest that the initial marginally significant shift of the
mean observed WAS in the short extremes is primarily driven by
the most extreme short individuals. Therefore, in general, as one
selects individuals with more extreme short stature, in particular
those with heights below the 0.25 percentile, the common variants
play a much smaller role in explaining stature, indicating that
there must be other factors contributing to the phenotypic
variation in these extremely short individuals.
Low frequency or rare variants with larger effect sizes
could explain the phenotypic variation in the short
extremes
We hypothesized that lower frequency and rare genetic variants
with larger effect sizes than the common variants may explain the
phenotypic variation in the short extremes. To test this hypothesis,
we performed population simulations with rare-variants of various
allele frequencies and effect sizes, and asked if our observed data
were consistent with these simulated scenarios (Figure 3; Figure
S4; Figure S5). As a negative control, we first modeled an
additional 180 SNPs, each with allele frequency of 0.3 and average
effect sizes of 20.05 SD, which is similar to the allele frequency
and effect size for previously discovered common variants
associated with height. In this simulation, the mean WAS
distribution did not change, indicating that adding additional
common variants of similar effect sizes cannot explain the
phenotypic variation in the short extremes. We then modeled a
single rare variant of very large effect: frequency 0.005 and effect
size of 24 SD. In this model, the mean WAS distribution in the
extremely short individuals shifts more than we observed in our
population. This simulation essentially excludes the possibility of a
0.5% variant of very large effect within our cohort. Such a variant
would also be likely to be discovered in linkage studies of several
thousand sib-pairs [6].
However, there are several rare variant models that would likely
not have been detected in previous linkage analyses of height and
generate a shift in the mean WAS consistent with our observed
data (Figure 3; Figure S4; Figure S5). One such possibility is a
single low frequency variant (allele frequency=0.005) with an
effect size of 22 SD; another model consistent with our data
includes 10 variants each with an allele frequency of 0.005 and a
moderate effect size of 21 SD. These simulations suggest that
individuals with very short stature may harbor small numbers of
low frequency variants of moderately large effect or a greater
number of low frequency variants of moderate effects contributing
to their short stature. This result stands in contrast to the
remainder of the height distribution in which a polygenic effect of
common and rare variants with small effects could explain the
majority of the heritability of height, even though only a small
Figure 1. Plot of weighted allele scores (WAS) against Height Z-
scores for HUNT and FINRISK cohorts. The plot shows the WAS,a
measure of the genetic prediction of height by known common
variants, against the height Z-scores. The tall individuals (Z-score.2.14)
have generally larger WAS than the short individuals (Z-score,22.14).
Individuals from the HUNT study are labeled blue and individuals from
the FINRISK study are labeled red.
doi:10.1371/journal.pgen.1002439.g001
Common Variants9 Effects on Height Extremes
PLoS Genetics | www.plosgenetics.org 3 December 2011 | Volume 7 | Issue 12 | e1002439Common Variants9 Effects on Height Extremes
PLoS Genetics | www.plosgenetics.org 4 December 2011 | Volume 7 | Issue 12 | e1002439percentage of height-associated common variants have been
identified.
Sibling analysis provides support for a different genetic
architecture in extreme short individuals
To provide further support for a different genetic architecture in
individuals in the extreme short tails we performed an analysis in
siblings from the HUNT study. We queried the entire HUNT
database (N=106,455) and identified 21,365 siblings pairs. The
correlation of age and gender adjusted height between siblings was
high (r=0.466). We then identified 98 individuals (aged between
20–70 yrs) with a Z-score,22.81 (,0.25% tails) and 80 with a Z-
score.2.81 who also had at least one sibling in the database (the
results are similar if we use inverse normal transformation). The
average height Z-score for the siblings of the extreme short group
was 20.97 (95% CI: 20.80, 21.15); the average Z-score for the
full siblings of the extreme tall group was 1.29 (95% CI: 1.14, 1.45)
which are significantly different (t-test, p=0.007 after reversing
signs for the short group). We then performed this same analysis
for the 0.25% to 1.5% tails individuals and there was no significant
difference in z-scores of siblings between the short (21.05 95% CI:
21.13, 20.97) and tall (1.11 95% CI: 1.03, 1.18) groups (t-test,
p=0.28). So the differential regression to the mean appears to be
limited to the shortest ,0.25% of individuals with this group
regressing more quickly than the tall extreme group. This is
consistent with the results we observe with the weighted allele
score (WAS) approach.
We do not have the twin data that would allow us to separate
out the environmental and genetic effects in this group and our
data is consistent with both. If the effect were due to genetics, then
a model with de novo mutations and/or multiple recessive rare
variants could cause an increased regression to the mean in
extremely short individuals, although there are other plausible
explanations.
Discussion
We have assessed whether common variants robustly associated
with height in the general population also associate with height at
the extreme tails of the height distribution. We further tested
whether this association is to the extent expected under a purely
polygenic model. By genotyping ,160 height SNPs identified
from the GIANT study [2] (that explain ,10% of the population
variation in height) in individuals from the ,1% tails of height
from two large population based cohorts, we have shown that the
polygenic model can explain the associations in the ,1% tails of
height. However, our data indicate that the polygenic model starts
to break down in extreme short individuals near the 0.25
percentile cut off. This conclusion is supported by our sibling
analysis, which demonstrated that siblings in the 0.25% short tail
regress to the mean more than those in the 0.25% tall group.
Interestingly, the overall height distribution also shows a slight
asymmetric deviation from normality, with an excess of individuals
with extremely short stature but not for extremely tall stature.
While in general the individuals in the ,1% tails carry as many
height increasing alleles as would be predicted based on their
height, there was a clear deviation for individuals in the shortest
0.25% tail. On average, these individuals carry significantly more
‘‘tall’’ alleles at the 160 SNPs than would be expected if common
alleles were explaining their short stature. This suggests that the
heights of these individuals are explained by factors other than
common variants. Our simulations suggest that rare variants could
explain this difference in the 0.25% shortest tail. For example, 10
rare variants with modest effects on height (1SD) are consistent
with our observed data, as is a single variant with a 2SD effect.
The sibling analysis also suggests a role for de novo or multiple
recessive variants in the extreme short individuals. While rare
height-decreasing variants of large effect are a plausible explana-
tion, there are many other genetic models consistent with our data,
including a mixture of height-decreasing with a smaller number of
height-increasing rare variants, or variants having non-additive
effects. While non-additive genetic effects could explain the data,
no evidence was found for dominance or gene-gene interaction
effects for the SNPs used in this study in the original GIANT
publication [2]. It is also possible that these individuals are short
for non-genetic reasons. One could suggest that these individuals
are short because of differences in ancestry, but we have taken
steps to remove any possible ethnic outliers from our extremes (See
Materials and Methods, Figure S6 and Figure S7). Measurement
or recording error is another possibility, although the fact that the
tall group does not show this effect (which presumably is equally
likely to contain measurement error as the short group) suggests
this is an unlikely explanation. Non-genetic factors could also be a
possibility, for example, poor early-life nutrition, severe infection,
or other chronic childhood diseases could have prevented these
individuals from reaching their genetic height potential.
This result also suggests that these families would be good
candidates to investigate in sequencing studies, as they may be
enriched for rare or de novo, higher penetrance alleles. More
generally, the weighted allele score (WAS) method developed here
could be used to select individuals to sequence in the search for
these types of rarer variants, not only for height but also for other
polygenic traits and diseases. Specifically, individuals in the
extreme tails of a trait distribution who have an unexpectedly
high or low weighted allele score may be particularly useful to
sequence, especially if multiple relatives with these characteristics
were present in the extreme tails.
Our study also demonstrates empirically that selecting individ-
uals from the extreme tails of a complex trait distribution is an
efficient approach for genetic studies, as was proposed both for
linkage studies [7,8] and association studies [9,10]. Despite a quite
modest sample size (N,1000), we replicated a large fraction of the
individual SNPs identified in the GIANT study in our extreme
height analysis. Ninety-one percent of the SNPs had odds ratios
that were directionally consistent with the direction in the
published GIANT study (p,0.0001), and 35% (49/141) of SNPS
had p,0.05 in the consistent direction. Our analyses also
demonstrate that, outside of the 0.25% tails, this level of
association is entirely consistent with that expected given the
extreme tail ascertainment of our samples and the individual SNP
continuous distribution effect sizes. Given this result, the
ascertainment of our 923 samples from the ,1% to 0.25% tails
Figure 2. Comparison of the observed versus simulated mean weighted allele score (WAS) in the combined cohort. The plot shows the
result of comparing the mean WAS of the short and tall individuals observed from both the HUNT and FINRISK cohorts against that obtained from
simulation. Each row represents a different stratification of the extremes. The percentiles and number of individuals in the short and tall extreme
respectively are listed for each stratum. The p-values represent the comparison between the observed and simulated mean WAS. The observed mean
WAS for the tall individuals are not different from the simulation in any of the strata. The observed mean WAS for the short individuals is not different
from the simulation in the first stratum. As a progressively more extreme sample is used, the short individuals’ mean WAS becomes progressively
more significantly different than the simulation.
doi:10.1371/journal.pgen.1002439.g002
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randomly selected from the general population for a variant
explaining approximately 0.1% of the variation in height. Indeed,
the ability to detect associations in samples ascertained for extreme
phenotypes has been recently demonstrated in studies of bone
mineral density [11], body mass index [12], triglyceride levels [13],
and type 2 diabetes (using a liability threshold model [14]). Also,
our results suggest that the statistical power of detecting these small
effect variants would be reduced if we were to include the most
extreme tails of the phenotypic distribution (in our case, the
shortest 0.25% of individuals), consistent with predictions made
based on simulation studies of mixtures of common and rare
variants [15]. Nonetheless, our findings suggest that the use of
individuals with the most extreme phenotypes could be particu-
larly valuable to detect rarer variants with larger effect sizes more
efficiently.
In conclusion, we have shown that common genetic variants
associated with height in the general population are also associated
with height at the ,1% tails of the height distribution. Our data
suggest that common variants play less of a role, and the effect of
rarer larger-effect alleles and/or strong environmental factors start
to predominate around the 0.25% extreme. This finding may also
have broader implications for studies of disease, in that the
polygenic model may apply well to those diseases that represent
the tails of an underlying normal distribution, but perhaps less well
to diseases that correspond to more extreme phenotypes.
Materials and Methods
Ethics statement
Both studies were conducted according to the principles
expressed in the Declaration of Helsinki. Attendance was
voluntary, and each participant signed a written informed consent
including information on genetic analyses. Local institutional
review boards approved study protocols.
Subjects
The HUNT study. The Nord-Trøndelag Health Study
(HUNT) is a comprehensive population based health study (www.
ntnu.edu/hunt) with personal and family medical histories on
approximately 120,000 people from Nord-Trøndelag County,
Norway, collected during three intensive studies (HUNT 1, 2, and
3). Inviting all citizens aged 20 and over, information was collected
from self-reported questionnaires consisting of .200 health-related
questions, standardized clinical examinations, urine and non-fasting
venous blood sample. The population in Nord-Trøndelag County is
ethnically homogeneous, ,3% of non-Caucasian ethnicity, making
it especially suitable for epidemiological genetic research. Height
was measured by trained personnel to the nearest 1.0 cm with the
participants wearing light clothes without shoes according to
standardized methods [16].
For this study we sourced data from HUNT 2 (1995–97) in
which 65,258 individuals participated (71.2% of invited). We
generated age and gender standardized height for the whole
population, and selected the shortest 1000 individuals and the
tallest 1000 individuals from the 54,909 participants aged between
18 and 70 yrs. We removed known 1st degree relatives based on
information from the Medical Birth Registry of Norway, those
reporting to be living outside of Norway their first year of life, and
those with low DNA concentrations. We then genotyped the
remaining shortest 471 individuals (,22.14 SDs) and the tallest
479 individuals (.2.14 SDs) from the cohort. Mean height and
age of the extreme tails are given in Table S5. We also genotyped
1,458 individuals of all ages with a Z-score between +/22 SDs as
our middle group.
The FINRISK Study. FINRISK is a Finnish national survey
on risk factors of chronic and non-communicable diseases. It is
carried out every five years since 1972 using independent, random
and representative population samples from different parts of
Finland [17]. For this study, we selected individuals from 4
different sub-populations divided by geography (East vs. West
Finland) and gender (Table S6). Individuals aged 25 to 74 years
were included. We then took approximately the tallest and shortest
50 individuals (Table S6) from each tail of the distribution from
each sub-population (extremes) and performed genotyping.
Genotyping and quality control
The HUNT study. Blood sampling was done whenever
subjects attended HUNT 2. DNA was extracted from peripheral
blood leukocytes from whole blood or blood clots stored in the
HUNT Biobank, using the Puregene kit (Gentra Systems,
Minneapolis, MN) manually or with an Autopure LS (Gentra
Systems). Laboratory technicians were blinded to the results of the
height measurements. Details on the DNA extraction and the
HUNT Biobank are described elsewhere [16].
Genotyping of short and tall individuals were done at the
Norwegian University of Science and Techonology, Norway using
the iSelect Metabochip (Illumina, San Diego, CA) and the
Infinium HD ultra protocol. Each 96-well plate included both
tall and short individuals and one sample of identical reference
DNA. Genotype calling was done using GenTrain version 2.0 in
GenomeStudio V2010.3 (Illumina, San Diego, CA). Genotyping
of the middle group was done on the Metabochip at the Center for
Inherited Disease Research (CIDR, MD) and called with
BeadStudio 3.3.7 with Gentrain version 1.0 (Illumina, San Diego,
CA).
Samples that did not meet a 99% completion threshold were
excluded from further analysis (N=19; 0.7%). Additional post-
Figure 3. Comparison of the observed versus simulated mean WAS with models incorporating additional variants. The plot shows the
result of comparing the mean WAS of the short and tall individuals observed from both the HUNT and FINRISK cohorts against that obtained from
simulation with different scenarios of additional variants. All rows use the approximate 1.5% tails of the height distribution as extremes, resulting in
566 short and 648 tall individuals. The 1
st row shows the result where the model has no additional variants affecting height and thus is identical to
that from the 2
nd row of Figure 2. The 2
nd row shows a model where there are 180 additional common variants that slightly decreases height (allele
frequency=0.3 and effect size (b)=20.05). This model does not result in any significant change to the simulated WAS of the short individuals and the
observed WAS is still significantly different (p=0.00756). The 3
rd row shows a model where there is 1 additional low frequency variant with a large
height decreasing effect (allele frequency=0.005 and effect size (b)=24). This model results in a large shift in the simulated WAS of the short
individuals to the right. The observed WAS is still significantly different (p=4.54610
28) than the simulation but in the opposite direction and thus is
not consistent with our data. The 4
th row shows a model where there is 1 additional low frequency variant that decreases height significantly (allele
frequency=0.005 and effect size (b)=22). This model results in a shift in the simulated WAS of the short individuals to the right such that the
observed WAS is no longer different from the simulation (p=0.544). The 5
th row shows a model where there are 10 additional low frequency variants
that moderately decreases height (allele frequency=0.005 and effect size (b)=21). This model also results in a shift in the simulated WAS of the short
individuals to the right such that the observed WAS is no longer different from the simulation (p=0.39). The final two models are consistent with our
observed data.
doi:10.1371/journal.pgen.1002439.g003
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first-degree relatedness (pi-hat .0.2; N=152, 6.3%) were done
using PLINK [18]. Ethnic outliers (N=174, 7.2%) were excluded
using the EIGENSTRAT software package [19]. After quality
assessment 2,063 individuals (85.7%) remained for further
analysis, 385 (81.2%) short, 456 (95.2%) tall and 1,224 (83.9%)
individuals in the middle group.
106 SNPs of the 180 GIANT height hits were directly typed on
the Metabochip. In addition, we used the SNP Annotation and
Proxy Search to map 54 of the remaining 74 SNPs with a
HapMap r2.0.8 linkage disequilibrium proxy result [20]. These
160 SNPs (i.e. 106 directly typed and 54 proxies) were used in
subsequent analyses. All SNPs showed a genotyping success rate
.98% and were in Hardy Weinberg equilibrium.
The FINRISK study. We directly genotyped the samples for
the 180 previously identified height SNPs. The genotyping was
done at Children’s Hospital Boston using Sequenom iPLEX
genotyping (Sequenom, Inc, San Diego, CA, USA). In total, 186
short individuals and 192 tall individuals were successfully
genotyped for 158 SNPs. All 158 SNPs had a genotyping
success rate $90% and the overall genotyping rate was 97.85%
(Table S7). One of these SNPs (rs1809889) is not part of the 180
GIANT SNPs, but data were available for this SNP from the
GIANT meta-analysis so it was included in our analysis.
We genotyped an additional 49 ancestry informative markers
(AIMs) to identify ethnic outliers [21]. We inputted genotype data
from our subjects as well as the reference HAPMAP samples
(CEU, YRI, CHB+JPT) for the 49 AIMs together with 130 height
SNPs into Structure 2.3.3 [22]. We detected 5 ethnic outliers with
.10% Asian ancestry who were excluded from further analysis
leaving a total of 181 short and 192 tall individuals as our
FINRISK study group.
Statistical analysis
Individual SNP analysis. For FINRISK, we calculated the
observed odds ratio for each of our 158 SNPs using the Cochran-
Manzel-Hansel test, which is a stratified chi-square test. We
stratified the individuals into 4 sub-cohorts based on geography
and gender (Table S6) and performed the test using PLINK [18].
The observed odds-ratio for each SNP was recorded, along with
the 95% confidence interval. For HUNT the observed odds-ratio
and 95% confidence intervals and the single association analysis
was performed using logistic regression in PLINK.
For both cohorts, we calculated the expected odds ratio for each
SNP by estimating the odds of the height-increasing versus the
height-decreasing allele in both the tall extremes (cases) and the
short extremes (controls) assuming a standard normal distribution
for standardized height, i.e. height,Normal(0,1). For a given SNP,
we defined the height-increasing effect size as b and the height-
increasing allele frequency as p. The mean height for the height-
increasing allele would be Mi=b p and the mean height for the
height-decreasing allele would be Md=2b (12p). The variance of
height for the both alleles would be V=12b
2 p( 1 2p). We then
calculated the odds of observing the height-increasing allele versus
the height-decreasing allele for both the tall extremes (cases) and
the short extremes (controls) by taking the ratio of the probabilities
of each allele being seen in the cases and the controls respectively.
These are calculated as:
Oddscases~
ð?
2:326
N(xDMi,V)dx
ð?
2:326
N(xDMd,V)dx
Oddscontrols~
ð{2:326
{?
N(xDMi,V)dx
ð{2:326
{?
N(xDMd,V)dx
where N(x|M,V) denotes the density function at x of a Normal
distribution with mean M and variance V. We use a cut-off of +/
22.326 to denote the approximate 1% tails. We then calculated
the expected odds-ratio by taking the ratio between Oddscases over
Oddscontrols, i.e.
Expected Odds Ratio~
Oddscases
Oddscontrol
To assess whether individual SNPs had odds ratios significantly
different from expectation, we generated upper and lower 95%
confidence limits for the expected distribution based on the
GIANT beta and standard errors estimates as above, and used the
natural log of these confidence limits to estimate an approximate
standard error for the expected odds ratio, i.e.
SEExpected OR~
ln(Upper){ln(Lower)
2|1:96
We then assessed significance by a Z-test of the difference between
observed odds ratio and expected odds ratio to obtain the Zscore,
i.e.
Zscore~
ln(ORobserved){ln(ORexpected)
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SEObserved OR
2zSEExpected OR
2
q
Meta-analysis. The HUNT and FINRISK studies
genotyped different sets of SNPS, with only 98 of the SNPs
matching exactly across the studies. We therefore used forty-three
of the HUNT SNPs that had r
2.0.8 HapMap proxies with a
genotyped FINRISK SNPs (Table S3). We used the inverse
variance method to meta-analyze the odds ratios for these 141
SNPs from the two studies. As opposed to the individual studies,
where study specific allele frequencies were used, we used the
GIANT allele frequency information to generate the expected
odds ratios for the meta-analysis. This did not appreciably affect
the results for individual SNP analysis within the individual
studies, and the meta-analyzed results were consistent to those in
the two individual studies.
Modeling the Weighted Allele Score (WAS). To calculate
the Weighted Allele Score (WAS) for each individual, we took the
sum of the effective allele dosages of the height SNPs multiplied by
their respective estimated effect sizes (bs) using the Stage 1 betas
from the GIANT study, as shown in the formula below.
WAS~
X N
i~1
bi|SNPi{a
b and SNP are the effect size and effective allele dosage (0, 1 or 2)
of the height SNPs and WAS is the weighted allele score. N is the
total number of SNPs available to calculate the weighted allele
score. a is the mean of the sum such that the expected WAS is 0 as
shown by the formula below.
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X N
i~1
2|bi|Frequencyi
Frequency is the allele frequency of the effect allele obtained from
the Finnish or HUNT estimates.
We calculated the statistical difference between the WAS of the
short versus the tall individuals by performing a 2-tailed 2-sample
t-test to obtain the respective p-value. All the calculations were
done using the R statistical software package.
Obtaining Finnish allele frequency estimates. The allele
frequency estimate for each SNP was obtained by taking only the
Finnish individuals from the GIANT height study and calculating
the expected allele frequency. The cohorts used were the FUSION
NIDDM Case control study from Finland, the GenMets Case
control study from Finland and the FINRISK component of the
MIGen cohort. The total number of individuals used for obtaining
the estimates is 3618.
Simulating the distribution of WAS under the null
model. The null model assumes that the only factors
determining height (Z-score) are the cumulative additive effects
of the GIANT height SNPs and noise. We modeled the Z-score
with the formula below.
Zscore~WASzN(0,s2
remaining)
Zscore is the height Z-score, N(0, s
2
remaining) is a normally
distributed random variable with mean 0 and variance
s
2
remaining. s
2
remaining is calculated such that the variance of
Zscore is 1, i.e. s
2
remaining is 12var(WAS). The variance of WAS can
be calculated with the formula below,
var(WAS)~
X N
i~1
2|b
2
i |Frequencyi|(1{Frequencyi)
On the other hand, a simulated individual’s effective allele dosage
is obtained by sampling from a set of binomial distributions with
N=2 and p being the allele frequencies of each SNP. The
simulated effective allele dosages can then be used to calculate
each individual’s WAS. The simulation approach for each cohort
was modeled to mirror the methods of subject selection.
Simulating FINRISK. For the FINRISK study, the
simulations were performed using the following steps. We first
generated the effective allele dosages for each SNP for 200,000
individuals by random sampling. We then randomly sampled
4271, 6582, 5025 and 7610 individuals to represent the 4 sub-
populations and obtained their Z-scores using the previously
described modeling. For each subgroup, we picked the
appropriate number of the most extreme individuals to mimic
the actual sample selection. We then pooled the short and tall
extremes together and randomly dropped individuals to obtain
exactly 181 short extremes and 192 tall extremes. We then
randomly drop SNPs from the simulated individuals to mimic
the missing genotype rate in FINRISK and then calculate the
Weighted Allele Score (WAS) for each simulated individual.
This simulation process was repeated 10,000 times. For the
stratified analyses of various height cut-offs, we adjusted the
numbers of selected individuals in each strata by taking the floor
of the expected number of individuals in that strata. In our
cohort, the top 0.5% extremes included 21, 32, 25 and 38
individuals from each tail of the 4 sub-populations respectively,
and for the top 0.25% extremes included 10, 16, 12 and 19
individuals from each tail of the 4 sub-populations. For the top
,1% to 0.25% extremes, we included all our extremes but
excluded the top 10, 16, 12 and 19 individuals from each tail of
the 4 sub-populations.
Simulating HUNT. The simulations for HUNT were
performed as follows. We generated the effective allele dosages
for each SNP for 400,000 individuals by random sampling. We
then randomly selected 50,000 individuals and obtained their Z-
scores.
We then selected all short and tall extremes with a Z-score cut-
off of 22.14 and +2.14 respectively. Next, we randomly selected
385 short extremes and 456 tall extremes and calculated the WAS.
This process was repeated 10,000 times. As in the FINRISK
simulation, the number of individuals varies for each stratified
analysis. Because we performed stratified analyses for varying
levels of height cut-offs, our definition for the top 0.5% extremes is
a Z-score cut-off below 22.57 and above +2.57 and for the top
0.25% extremes is a Z-score cut-off below 22.81 and above +2.81.
For the top ,1.5% to 0.25% extremes, we used only extremes that
had Z-scores between 22.14 and 22.81 for the short extremes
and between 2.14 and 2.81 for the tall extremes.
Determining if the mean observed WAS is significantly
different from the simulated expectation. We evaluated the
significance of the mean observed WAS by determining the p-value
of the mean observed WAS from the null distribution of the mean
WAS obtained from the simulations. The two-tailed p-value is
calculated by evaluating the mean observed WAS from
Normal(msimulation, s
2
simulation) where msimulation is the mean of the
mean WAS and s
2
simulation is the variance of the mean WAS from
the simulations.
Modeling rare-variants with moderate to large effect
sizes. Modeling the rare-variant effect into the simulation is
accomplished by adding an additional rare-variant term into the
calculation of the height Z-score without changing the definition of
WAS as shown in the equation below.
Zscore~WASz(
X n
i~1
Bi|Vi){arvzN(0,s2
remaining)
where n is the number of independent rare-variants, B represents
the effect size of the rare-variants, and V is the allele dosage of the
rare-variant. arv is the mean of the rare-variants score such that
the rare-variants do not change the expected Z-score, i.e. the
expected Z-score is still 0. Similarly, arv can be calculated by the
following formula,
arv~
X n
i~1
2|Bi|Fi
s
2
remaining in this case will have to be adjusted for the rare-variants
such that the variance of the Z-score remains at 1, i.e. s
2
remaining is
12var(WAS)2var(S BV ). F is the allele frequency of the rare-
variants. Simulations done with modeling rare-variants are
identical to the prior simulations of FINRISK or HUNT except
that the new terms are used for calculating the Z-score.
Supporting Information
Figure S1 QQ Plot of p-values for individual SNPs based on the
meta-analysis of HUNT and FINRISK. The figure shows a Q-Q
plot of the p-values of the difference between the observed odd-
ratios and the expected odd-ratios.
(TIF)
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weighted allele score (WAS) in the HUNT study. The plot shows
the result of comparing the mean WAS of the short and tall
individuals observed in the HUNT cohort against that obtained
from simulation. Each row represents a different stratification of
the extremes identical to those defined in Figure 2. The plot also
show the mean WAS of 1224 non-extreme individuals taken from
the middle of the height distribution. There is no difference
between the mean WAS of the non-extreme individuals from that
obtained from simulation (p=0.56).
(TIF)
Figure S3 Comparison of the observed versus simulated mean
weighted allele score (WAS) in the FINRISK study The plot shows
the result of comparing the mean WAS of the short and tall
individuals observed in the FINRISK cohort against that obtained
from simulation. Each row represents a different stratification of
the extremes identical to those defined in Figure 2.
(TIF)
Figure S4 Comparison of the observed versus simulated mean
WAS by incorporating additional variants (HUNT only). The plot
shows the result of comparing the mean WAS of the short and tall
individuals observed from only the HUNT cohort against that
obtained from simulation with different scenarios of additional
variants. Each row represents a different scenario identical to those
defined in Figure 3.
(TIF)
Figure S5 Comparison of the observed versus simulated mean
WAS by incorporating additional variants (FINRISK only). The
plot shows the result of comparing the mean WAS of the short and
tall individuals observed from only the FINRISK cohort against
that obtained from simulation with different scenarios of
additional variants. Each row represents a different scenario
identical to those defined in Figure 3.
(TIF)
Figure S6 Principal component plots from the HUNT study for
the 0.25% short individuals versus all tall individuals. The first two
principal components obtained from Eigenstrat analysis for the
samples in the HUNT study are plotted. There is no significant
difference in principal components between the short and tall
groups.
(TIF)
Figure S7 Principal component plots from the HUNT study for
the 0.25% short vs. the 0.25% tall individuals. The first two
principal components obtained from Eigenstrat analysis for the
samples in the HUNT study are plotted. There is no significant
difference in principal components between the short and tall
groups.
(TIF)
Table S1 Individual SNP analysis for HUNT cohort. The table
shows the results for the SNPs used in the individual association
analysis in the HUNT cohort.
(XLS)
Table S2 Individual SNP analysis for FINRISK cohort. The
table shows the results for the SNPs used in the individual
association analysis in the FINRISK cohort.
(XLS)
Table S3 Meta-analysis of individual SNPs for HUNT and
FINRISK cohort. The table shows the results for the SNPs used in
the meta-analysis of the HUNT and FINRISK cohorts.
(XLS)
Table S4 Meta-analysis of individual SNPs for HUNT and
FINRISK cohort using only the top 0.25% tails. The table shows
the results for the SNPs used in the meta-analysis of the HUNT
and FINRISK cohorts using only the top 0.25% tails as extremes.
(XLS)
Table S5 Mean height and age of the individuals in the extreme
tails of HUNT. Table of various stratification of extremes, the
number of individuals in each strata separated by gender with
their corresponding mean height (cm) and age (years) for the
HUNT cohort.
(XLS)
Table S6 The FINRISK cohort divided into 4 sub-populations.
The table shows the number of individuals used for each of the
FINRISK sub-populations. The FINRISK cohort is sub-divided
between male and female as well as individuals from east and west
Finland.
(XLS)
Table S7 The genotyping rate of FINRISK. The table shows
the number of SNPs genotyped in FINRISK and the genotyping
rate for the short and tall extremes. The rate is calculated based on
having 181 short individuals and 192 tall individuals.
(XLS)
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